Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05614739
Title	A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Eli Lilly and Company
Indications	transitional cell carcinoma Advanced Solid Tumor
Therapies	LOXO-435 + Pembrolizumab LOXO-435
Age Groups:	adult \| senior
Covered Countries	USA \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS